Reproductive Medicine Center, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai, China.
Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai, China.
Front Endocrinol (Lausanne). 2023 Jul 3;14:1170727. doi: 10.3389/fendo.2023.1170727. eCollection 2023.
Many patients who undergo assisted reproductive technology (ART) suffer from recurrent implantation failure (RIF). The addition of hyaluronic acid (HA) to the transfer medium is one of several methods to improve pregnancy outcomes. We investigated whether HA could improve the live birth and clinical pregnancy rates of RIF patients.
This study included 248 RIF patients, who were divided into two groups: the control (CTL) group (n=137), which received transfer medium without HA, and the HA group (n=111), which received transfer medium with HA. The two groups were compared according to the ART outcome.
The primary outcomes were the clinical pregnancy and live birth rates. Secondary outcomes include a positive urine pregnancy test, the implantation, ongoing pregnancy, multiple pregnancy, clinical miscarriage, and ectopic pregnancy rates, foetal or congenital defects, obstetric complications, infant birth weight and any related adverse events. Regarding the primary outcomes, the clinical pregnancy rate was significantly higher in the HA group than in the control group, and there was no significant difference in the live birth rate (LBR) between the HA and control groups. Regarding the secondary outcomes, the implantation, multiple pregnancy and ectopic pregnancy rates were similar between the two groups.
Our findings supported the conclusion that HA can improve the clinical pregnancy rate of patients with RIF undergoing FET cycles, but the live birth rate was not significantly improved with the addition of HA to the traditional transfer medium.
许多接受辅助生殖技术(ART)的患者都经历过反复着床失败(RIF)。在转移介质中添加透明质酸(HA)是提高妊娠结局的几种方法之一。我们研究了 HA 是否可以提高 RIF 患者的活产率和临床妊娠率。
本研究纳入了 248 例 RIF 患者,将其分为两组:对照组(CTL 组,n=137),接受不含 HA 的转移介质;HA 组(n=111),接受含 HA 的转移介质。根据 ART 结果比较两组。
主要结局是临床妊娠率和活产率。次要结局包括尿妊娠试验阳性、着床、持续妊娠、多胎妊娠、临床流产和异位妊娠率、胎儿或先天性缺陷、产科并发症、婴儿出生体重以及任何相关的不良事件。关于主要结局,HA 组的临床妊娠率显著高于对照组,HA 组与对照组的活产率(LBR)无显著差异。关于次要结局,两组的着床、多胎妊娠和异位妊娠率相似。
我们的研究结果支持以下结论:HA 可以提高接受 FET 周期的 RIF 患者的临床妊娠率,但在传统转移介质中添加 HA 并不能显著提高活产率。